Brent Pfeiffenberger Acquires 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) CEO Brent Pfeiffenberger bought 52,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of $0.58 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer directly owned 3,322,990 shares in the company, valued at $1,927,334.20. This trade represents a 1.59% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Brent Pfeiffenberger also recently made the following trade(s):

• On Wednesday, November 19th, Brent Pfeiffenberger purchased 35,000 shares of Century Therapeutics stock. The stock was purchased at an average cost of $0.50 per share, with a total value of $17,500.00.
• On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,605.20.
• On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $14,605.20.

Century Therapeutics Stock Performance

NASDAQ:IPSC opened at $0.67 on Thursday. Century Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $1.19. The stock has a fifty day moving average of $0.56 and a 200 day moving average of $0.55. The firm has a market capitalization of $58.33 million, a price-to-earnings ratio of -2.09 and a beta of 1.80.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative return on equity of 10.01% and a negative net margin of 19.10%. Equities analysts forecast that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IPSC. Goldman Sachs Group Inc. lifted its position in Century Therapeutics by 26.9% in the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after purchasing an additional 38,052 shares during the last quarter. Nuveen LLC purchased a new position in shares of Century Therapeutics in the first quarter worth $75,000. Squarepoint Ops LLC raised its holdings in Century Therapeutics by 483.1% during the 3rd quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after buying an additional 195,573 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Century Therapeutics during the 2nd quarter valued at $51,000. Finally, Marshall Wace LLP bought a new stake in Century Therapeutics in the 2nd quarter worth $78,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on IPSC shares. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 20th. Finally, Leerink Partnrs downgraded Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Century Therapeutics has a consensus rating of “Hold” and a consensus price target of $3.40.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.